Good
Mostly Aligned
Patient Risk:
Low
Summary
Most factual label-aligned statements are consistent with the provided FDA label excerpts (active ingredient, indication, mechanism). However, several claims about generic availability/expectations and off-label-like timing/supply reasons are not addressed in the supplied label, leaving them unsupported.
Category Scores
Accurate Statements
Enablex’s active ingredient is darifenacin.
Section 1/Drug description excerpt: ENABLEX (darifenacin) extended-release tablets.
Enablex is used for overactive bladder symptoms.
Section 1: indicated for overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
Enablex treats overactive bladder symptoms by treating the underlying drug target (muscarinic receptors).
Section 12: Darifenacin is a competitive muscarinic receptor antagonist; consistent with antimuscarinic action on the urinary bladder.
Unsupported Statements
Whether a generic darifenacin is available depends on the country and local approvals.
No statement in the provided label excerpts addresses generic availability by country/market.
Generic availability varies by market.
Not addressed in the provided label excerpts.
A generic version of Enablex, if available where you live, should list darifenacin as the active ingredient.
No statement in the provided label excerpts addresses how generics are listed or regulatory labeling practices.
A generic version should have the same strength as the prescription (such as 7.5 mg or 15 mg).
The provided label excerpts do not discuss generic strength equivalence expectations.
A properly approved generic is expected to have the same active ingredient as the brand product.
Not addressed in the provided label excerpts.
A properly approved generic is expected to work similarly to the brand product.
The provided label excerpts do not discuss expectations of generic performance equivalence.
Exact dosing and side effects can vary from person to person.
The provided label excerpts do not make this generalization in the way asserted, and no comparable statement about variability in dosing/side effects by person is included in the supplied text.
Even if patent or brand exclusivity has ended in some places, generic launch timing can differ due to regulatory approval timelines for that specific market.
The provided label excerpts do not discuss patent/exclusivity effects or generic launch timing.
Even if patent or brand exclusivity has ended in some places, generic launch timing can differ due to manufacturing and supply availability.
Not addressed in the provided label excerpts.
Enablex is the brand name for darifenacin.
While the label excerpt shows ENABLEX (darifenacin), the specific claim phrased as 'brand name for darifenacin' is not explicitly stated in the provided text.
The generic name is darifenacin.
Not explicitly stated as a 'generic name' statement in the provided excerpts, though darifenacin is identified as the active ingredient.
Contradictions
Important Omissions
Any label-consistent dosing/administration details for ENABLEX (e.g., starting dose 7.5 mg once daily; possible increase to 15 mg after two weeks; swallow whole; not chewed/crushed) were not claimed by the AI response, preventing a dosage alignment check.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No contraindications, warnings, drug interactions, or specific dosing instructions were asserted in the provided response; main unsupported areas concern generic availability/timing/general expectations rather than safety-critical dosing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims about generic availability, timing, and expected equivalence are not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit statements to label-supported facts (active ingredient, labeled indication, mechanism) and avoid assertions about generic availability/equivalence timing unless supported by label text provided.